Endocrine Withdrawal Syndromes
The DOI matches its Crossref record; 174 of the 176 references it cites were found in a registry or an index.
Abstract
Hypersecretion of endogenous hormones or chronic administration of high doses of the same hormones induces varying degrees of tolerance and dependence. Elimination of hormone hypersecretion or discontinuation of hormone therapy may result in a mixed picture of two syndromes: a typical hormone deficiency syndrome and a generic withdrawal syndrome. Thus, hormones with completely different physiological effects may produce similar withdrawal syndromes, with symptoms and signs reminiscent of those observed with drugs of abuse, suggesting shared mechanisms. This review postulates a unified endocrine withdrawal syndrome, with changes in the hypothalamic-pituitary-adrenal axis and the central opioid peptide, in which noradrenergic and dopaminergic systems of the brain act as common links in its pathogenesis. Long-term adaptations to hormones may involve relatively persistent changes in molecular switches, including common intracellular signaling systems, from membrane receptors to transcription factors. The goals of therapy are to ease withdrawal symptoms and to expedite weaning of the patient from the hormonal excess state. Clinicians should resort to the fundamentals of tapering hormones down over time, even in the case of abrupt removal of a hormone-producing tumor. In addition, the prevention of stress and concurrent administration of antidepressants may ameliorate symptoms and signs of an endocrine withdrawal syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucocorticoid withdrawal syndrome occurs due to dependence on supraphysiologic glucocorticoids while decreasing the dose of glucocorticoids (70-72).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [70]
In the citing paper
“GWS likely occur due to physical dependence on supraphysiologic endogenous cortisol secretion prior to curative adrenalectomy.”
From Extensive clinical experience: hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess (2018) · cites this paper as [8]
Citations
Cites
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Subgenual prefrontal cortex abnormalities in mood disorders
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, M. E. (1997) · Nature · doi:10.1038/386824a0 · Cited by 2,693
The Concepts of Stress and Stress System Disorders: Overview of Physical and Behavioral Homeostasis
Chrousos, G. P. (1992) · JAMA · doi:10.1001/jama.1992.03480090092034 · Cited by 2,689
Self-citationDrug abuse: hedonic homeostatic dysregulation
Koob, G. F., & Moal, M. L. (1997) · Science · doi:10.1126/science.278.5335.52 · Cited by 2,535
Frontal-subcortical circuits and human behavior
Cummings, J. L. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540080076020 · Cited by 2,262
Molecular and Cellular Basis of Addiction
Nestler, E. J., & Aghajanian, G. K. (1997) · Science · doi:10.1126/science.278.5335.58 · Cited by 1,313
Cingulate function in depression: a potential predictor of treatment response
Mayberg, H. S., Brannan, S. K., Mahurin, R. K., Jerabek, P. A., Brickman, J. S., Tekell, J. L., Silva, J. A., McGinnis, S., Glass, T. G., Martin, C. C., et al. (1997) · NeuroReport · doi:10.1097/00001756-199703030-00048 · Cited by 1,029
Effects of gonadal steroids in women with a history of postpartum depression
Bloch, M., Schmidt, P. J., Danaceau, M., Murphy, J., Nieman, L., & Rubinow, D. R. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.924 · Cited by 950
Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation
HOLSBOER, F., & BARDEN, N. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-2-187 · Cited by 852
Principles and Practice of Endocrinology and Metabolism.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-816_4 · Cited by 803
Research works printed but not linked: 1
- Lampit, 1998, Sleep activity in idiopatic short children: longer better sleep with growth hormone, Horm Res, 50, 120
Cited by
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
“Patients should be warned that this is common and expected (81).”
BackgroundYim, I. S., Tanner Stapleton, L. R., Guardino, C. M., Hahn-Holbrook, J., & Dunkel Schetter, C. (2015) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-101414-020426 · Cited by 749
“For example, withdrawal theories imply that the intricate system of hormonal adaptations established over the course of pregnancy is suddenly disrupted, which challenges the maternal organism to restore a new endocrine balance (e.g., Hochberg et al. 2003).”
BackgroundComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Maurer, M., Magerl, M., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören‐Pürsün, E., Banerji, A., Bara, N., Boccon‐Gibod, I., Bork, K., et al. (2022) · Allergy · doi:10.1111/all.15214 · Cited by 534
Maurer, M., Magerl, M., Ansotegui, I., Aygören‐Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A. S., et al. (2018) · Allergy · doi:10.1111/all.13384 · Cited by 513
“It is unclear whether stopping long-term prophylaxis with attenuated androgens should be performed by tapering off gradually over time.(167,168) The dose of androgens needed to control HAE attacks can vary between the equivalent of 100 mg every other day and 200 mg of danazol 3 times a day.”
BackgroundAnabolic–androgenic steroid dependence: an emerging disorder
Kanayama, G., Brower, K. J., Wood, R. I., Hudson, J. I., & Pope Jr, H. G. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02734.x · Cited by 294
“Finally, androgen withdrawal is also probably a complex phenomenon that shares multiple mechanisms with other endocrine withdrawal syndromes and with withdrawal from drugs of abuse—including changes in opioid peptide systems, the mesolimbic dopaminergic system and other central pathways [106].”
Seth, S., Lewis, A. J., & Galbally, M. (2016) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-016-0915-y · Cited by 266
“A number of researchers have suggested that the body normally self-adjusts to this withdrawal within the postpartum period but in cases of postnatal depression, an over-adjustment occurs, which leads to hypocortisolemia and triggers depressive symptoms [28, 29].”
BackgroundReincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Illicit anabolic–androgenic steroid use
Kanayama, G., Hudson, J. I., & Pope, H. G. (2010) · Hormones and Behavior · doi:10.1016/j.yhbeh.2009.09.006 · Cited by 257
“other central pathways (Hochberg et al., 2003).”
BackgroundBiermasz, N. R., van Thiel, S. W., Pereira, A. M., Hoftijzer, H. C., van Hemert, A. M., Smit, J. W. A., Romijn, J. A., & Roelfsema, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0669 · Cited by 254
“Also, long-term withdrawal eff ects may have led to irreversible alterations in perceived quality of life (28, 29).”
BackgroundQuality of Life in Patients after Long-Term Biochemical Cure of Cushing’s Disease
van Aken, M. O., Pereira, A. M., Biermasz, N. R., van Thiel, S. W., Hoftijzer, H. C., Smit, J. W. A., Roelfsema, F., Lamberts, S. W. J., & Romijn, J. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1375 · Cited by 253
“Finally, long-term endocrine withdrawal effects may have led to irreversible alterations in perceived quality of life (35).”
BackgroundIncidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208
“Glucocorticoids suppress prostanoid and platelet-activating factor production, and the reverse occurs upon withdrawal of steroid hormones (30).”
BackgroundYim, I. S., Glynn, L. M., Dunkel Schetter, C., Hobel, C. J., Chicz-DeMet, A., & Sandman, C. A. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.533 · Cited by 188
Maurer, M., Magerl, M. A. K., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören‐Pürsün, E., Banerji, A., Bara, N., Boccon‐Gibod, I., Bork, K., et al. (2022) · World Allergy Organization Journal · doi:10.1016/j.waojou.2022.100627 · Cited by 169
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Hypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects
Jacobson, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130036 · Cited by 144
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Cortisol and DHEA-S levels in pregnant women with severe anxiety
Leff-Gelman, P., Flores-Ramos, M., Carrasco, A. E. Á., Martínez, M. L., Takashima, M. F. S., Coronel, F. M. C., Labonne, B. F., Dosal, J. A. Z., Chávez-Peón, P. B., Morales, S. G., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02788-6 · Cited by 135
Treatment of anabolic–androgenic steroid dependence: Emerging evidence and its implications
Kanayama, G., Brower, K. J., Wood, R. I., Hudson, J. I., & Pope, H. G. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.01.011 · Cited by 152
“Hypogonadism combines with other neuroendocrine factors to create a wellcharacterized AAS withdrawal syndrome (Hochberg et al., 2003), mediated by a variety of cortical neurotransmitter systems (Kashkin and Kleber, 1989; Wood, 2008), and long Kanayama et al.”
BackgroundKino, T., Ichijo, T., Amin, N. D., Kesavapany, S., Wang, Y., Kim, N., Rao, S., Player, A., Zheng, Y.-L., Garabedian, M. J., et al. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0345 · Cited by 130
Self-citationMerke, D. P., Giedd, J. N., Keil, M. F., Mehlinger, S. L., Wiggs, E. A., Holzer, S., Rawson, E., Vaituzis, A. C., Stratakis, C. A., & Chrousos, G. P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2488 · Cited by 128
Self-citationBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Kanayama, G., Hudson, J. I., & Pope, H. G. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.02.008 · Cited by 146
A Review of Hypothalamic-Pituitary-Adrenal Axis Function in Chronic Fatigue Syndrome
Tomas, C., Newton, J., & Watson, S. (2013) · ISRN Neuroscience · doi:10.1155/2013/784520 · Cited by 98
From Malthus to motive: How the HPA axis engineers the phenotype, yoking needs to wants
Pecoraro, N. C., Dallman, M. F., Warne, J. P., Ginsberg, A. B., Laugero, K. D., la Fleur, S. E., Houshyar, H., Gómez-Oliver, F., Bhargava, A., & Akana, S. F. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.004 · Cited by 144
Yanase, T., Tajima, T., Katabami, T., Iwasaki, Y., Tanahashi, Y., Sugawara, A., Hasegawa, T., Mune, T., Oki, Y., Nakagawa, Y., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0242 · Cited by 104
Adrenal axis function after high‐dose steroid therapy for childhood acute lymphoblastic leukemia
Einaudi, S., Bertorello, N., Masera, N., Farinasso, L., Barisone, E., Rizzari, C., Corrias, A., Villa, A., Riva, F., Saracco, P., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21339 · Cited by 91
Seidlová‐Wuttke, D., Jarry, H., Christoffel, J., Rimoldi, G., & Wuttke, W. (2005) · Toxicology · doi:10.1016/j.tox.2005.05.001 · Cited by 91
Drug discontinuation effects are part of the pharmacology of a drug
Reidenberg, M. M. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183285 · Cited by 82
Hurtado, M. D., Cortes, T., Natt, N., Young, W. F., & Bancos, I. (2018) · Clinical Endocrinology · doi:10.1111/cen.13803 · Cited by 76
Sionov, R. V., Spokoini, R., Kfir‐Erenfeld, S., Cohen, O., & Yefenof, E. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00406-5 · Cited by 86
“Physiological levels of circulating GCs are essential for the maintenance of the proper central nerve system (CNS) function (de Kloet et al., 2008; Hochberg et al., 2003).”
BackgroundRetirada da corticoterapia: recomendações para a prática clínica
Alves, C., Robazzi, T. C. M. V., & Mendonça, M. (2008) · Jornal de Pediatria · doi:10.1590/s0021-75572008000300003 · Cited by 77
Withdrawal from glucocorticosteroid therapy: Clinical practice recommendations
Alves, C., Robazzi, T. C. V., & Mendonça, M. (2008) · Jornal de Pediatria · doi:10.2223/jped.1773 · Cited by 72
Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations
Alcubierre, D. D., Ferrari, D., Mauro, G. C. D., Isidori, A. M., Tomlinson, J., & Pofi, R. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02091-7 · Cited by 78
“Indeed, an intact CRH system in the brain is necessary for adequate mesolimbic dopaminergic function; its alteration contributes to inadequate stimulation of dopaminergic neurons terminating in the nucleus accumbens , fuelling anxiety and depression [280].”
BackgroundNieman, L. K., Castinetti, F., Newell-Price, J. D. C., Valassi, E., Drouin, J., Takahashi, Y., & Lacroix, A. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00588-w · Cited by 88
“GWS is characterized by clinical features consistent with cortisol deficiency despite the use of physiological (or even supraphysiological) glucocorticoid replacement therapy 202 .”
Glucocorticoid Therapy and Adrenal Suppression
Nicolaides, N. C., Pavlaki, A. N., Alexandra, M. A. M., & Chrousos, G. P. (2011) · Europe PMC (PubMed Central) · Cited by 71
Self-citationEndocrine effects of tobacco smoking
Τζιόμαλος, Κ., & Charsoulis, F. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02161.x · Cited by 84
“Many of the nicotine withdrawal symptoms of smokers who try to quit seem to be the body’s response to changes in cortisol levels (Hochberg et al ., 2003).”
BackgroundGlucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
He, X., Findling, J. W., & Auchus, R. J. (2022) · Pituitary · doi:10.1007/s11102-022-01218-y · Cited by 64
Hahn-Holbrook, J., Dunkel Schetter, C., Arora, C., & Hobel, C. J. (2013) · Clinical Psychological Science · doi:10.1177/2167702612470646 · Cited by 69
“…in pregnancy, followed by their subsequent, precipitous withdrawal, have been hypothesized to trigger postpartum depression in vulnerable individuals (Chrousos et al., 1998; Halbreich, 2005; Hochberg et al., 2003; Magiakou et al., 1996; Vitoratos, Papatheodorou, Kalantaridou, & Mastorakos, 2006).”
BackgroundMaurer, M., Magerl, M. A. K., Ansotegui, I. J., Aygören‐Pürsün, E., Betschel, S., Bork, K., Bowen, T., Boysen, H. B., Farkas, H., Grumach, A. S., et al. (2018) · World Allergy Organization Journal · doi:10.1186/s40413-017-0180-1 · Cited by 73
Sex Differences in Opioid-Mediated Effects: Role of Androgens
Sharp, J. L., Pearson, T., & Smith, M. A. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104522 · Cited by 72
German, A., Suraiya, S., Tenenbaum-Rakover, Y., Koren, I., Pillar, G., & Hochberg, Z. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0519 · Cited by 57
Self-citationSteroid withdrawal syndrome after successful treatment of Cushing’s syndrome: a reminder
Bhattacharyya, A., Kaushal, K., Tymms, D. J., & Davis, J. R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01953 · Cited by 54
“Alterations in the concentrations of a number of other mediators have been hypothesised to play a role in the development of the SWS, notably CRH and central noradrenergic and dopaminergic systems, reviewed in more detail by Hochberg et al. (3). There are few specific recommendations in standard endocrinology textbook…”
BackgroundNeurologic Complications of Chemotherapy and Radiation Therapy
Nolan, C. P., & DeAngelis, L. M. (2015) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000464179.81957.51 · Cited by 54
Evidence on Ergogenic Action of Glucocorticoids as a Doping Agent Risk
Duclos, M. (2010) · The Physician and Sportsmedicine · doi:10.3810/psm.2010.10.1817 · Cited by 53
Cushing's Syndrome and Adrenocortical Insufficiency Caused by Topical Steroids: Misuse or Abuse?
Güven, A., Gulumser, O., & Özgen, İ. T. (2007) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2007.20.11.1173 · Cited by 53
Glucocorticoids: A Doping Agent?
Duclos, M. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.10.001 · Cited by 55
“The interplay between central noradrenergic systems and GC is also involved in the physiology and physiopathology of GC-induced mood changes (euphoria, depression, and withdrawal syndrome).(6)”
BackgroundGlucocorticoids dose-dependently remodel energy stores and amplify incentive relativity effects
Pecoraro, N. C., Gómez-Oliver, F., & Dallman, M. F. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.03.010 · Cited by 50
Approach to the Patient With Glucocorticoid-induced Adrenal Insufficiency
Borresen, S. W., Klose, M., Glintborg, D., Watt, T., Andersen, M., & Feldt‐Rasmussen, U. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac151 · Cited by 47
Glucocorticoid withdrawal syndrome: what to expect and how to manage
Theiler‐Schwetz, V., & Prete, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000804 · Cited by 48
“Following surgical cure of endogenous CS, GWS symptoms are common and expected to start developing 3 to 10days postoperatively despite appropriate glucocorticoid replacement [10,16].”
BackgroundInfluentialPrenatal β-endorphin as an early predictor of postpartum depressive symptoms in euthymic women
Yim, I. S., Glynn, L. M., Schetter, C. D., Hobel, C. J., Chicz-DeMet, A., & Sandman, C. A. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.009 · Cited by 42
“, 2003), and it is preceded by physiological changes unique to pregnancy and parturition that may underlie vulnerability to postpartummood disorders (Halbreich, 2005a; Hochberg et al., 2003; Payne et al., 2009).”
InfluentialPerioperative Management of a Patient With Cushing Disease
Varlamov, E. V., Vila, G., & Fleseriu, M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac010 · Cited by 41
“Distinguishing between GC withdrawal from AI can be difficult [108]; therefore multidisciplinary clinician and nursing awareness about the possibility of adrenal crisis and prompt management is warranted.”
BackgroundChrousos, G. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401671101 · Cited by 37
Self-citationPost‐SARS sickness syndrome manifestations and endocrinopathy: how, why, and so what?*
Chrousos, G. P., & Kaltsas, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02361.x · Cited by 39
Self-citationSchuetz, P., Leuppi, J. D., Bingisser, R., Bodmer, M., Briel, M., Drescher, T., Duerring, U., Henzen, C., Leibbrandt, Y., Maier, S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0182 · Cited by 35
Iatrogenic adrenal insufficiency in adults
Martin‐Grace, J., Tomkins, M., O’Reilly, M., & Sherlock, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00929-x · Cited by 40
“…reduction in glucocorticoid levels following a period of supraphysiological exposure, either after successful treatment of endogenous hypercortisolaemia or after the reduction or cessation of exogenous glucocorticoids 61,117,118 , and is predicted by the severity of hypercortisolaemia 118,119 .”
Pope, H. G., & Kanayama, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3375-0_19 · Cited by 34
Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis
Chua, M. E., Silangcruz, J. M., Chang, S., Williams, K., Saunders, M. A., Lopes, R. I., Farhat, W. A., & Yang, S. S.-D. (2016) · PEDIATRICS · doi:10.1542/peds.2016-0495 · Cited by 32
Perioperative Considerations for Person-Centered Gender-Affirming Surgery
Tollinche, L. E., Rosa, W. E., & Rooyen, C. V. (2021) · Advances in Anesthesia · doi:10.1016/j.aan.2021.07.005 · Cited by 36
Is there a safe and effective way to wean patients off long‐term glucocorticoids?
Baker, E. H. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14679 · Cited by 38
“Candidates include CRH, vasopressin, pro-opiomelanocortin and the adrenergic system.(24) In the brain, exogenous glucocorticoids may alter neurotransmitters(23) and impair recovery from neuronal damage.”
BackgroundImpact of aerobic exercise intensity on craving and reactivity to smoking cues.
Rensburg, K. J. V., Elibero, A., Kilpatrick, M. W., & Drobes, D. J. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0032768 · Cited by 38
Self-administration of estrogen and dihydrotestosterone in male hamsters
DiMeo, A. N., & Wood, R. I. (2006) · Hormones and Behavior · doi:10.1016/j.yhbeh.2005.11.003 · Cited by 32
Zhang, C. D., Li, D., Singh, S., Suresh, M., Thangamuthu, K., Nathani, R., Achenbach, S. J., Atkinson, E. J., Van Gompel, J. J., Young, W. F., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad073 · Cited by 29
Perioperative considerations for transgender women undergoing routine surgery: a narrative review
Lennie, Y., Leareng, K., & Evered, L. A. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.01.024 · Cited by 32
Vogel, F., Braun, L., Zopp, S., Nowak, E., Schreiner, J., Benz, I., Rubinstein, G., Künzel, H., Ritzel, K., Kroiss, M., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad041 · Cited by 28
The effect of opium addiction on thyroid function tests
Gozashti, M. H., Mohammadzadeh, E., Divsalar, K., & Shokoohi, M. (2014) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-13-5 · Cited by 28
“But there are some reports claiming alterations of T3 and T4 levels that are mostly due to the direct effects of these substances on thyroid gland [22,23].”
BackgroundInfluentialCohen, D., & Recalt, A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496733 · Cited by 28
Glucocorticoid treatment and adrenal suppression in children: current view and open issues
Improda, N., Chioma, L., Capalbo, D., Bizzarri, C., & Salerno, M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02461-9 · Cited by 35
“GWS symptoms may overlap with symptomatic AI and/or with a relapse of the underly - ing disorder, including anorexia, nausea/vomiting, lethargy, arthralgia, myalgia, low grade fever, postural hypotension, and psychiatric symptoms such as anxiety, panic attacks and depression [59 ].”
InfluentialAyala, A. R., & Manzano, A. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1508-0 · Cited by 32
“withdrawal’ symptoms following remission despite adequate glucocorticoid replacement [45].”
BackgroundJohnston, D. T., Li, H. H., Craig, T., Bernstein, J. A., Anderson, J. T., Joseph, K., & Riedl, M. A. (2020) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.200106 · Cited by 26
Shimko, K. M., Piatkowski, T. M., Thomas, K. V., Speers, N., Brooker, L., Tscharke, B. J., & O'Brien, J. W. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.126340 · Cited by 31
The Central Effects of Androgenic-anabolic Steroid Use
Mędraś, M., Brona, A., & Jóźków, P. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000395 · Cited by 29
Perioperative Management of Endocrine Active Adrenal Tumors
Schreiner, F., Anand, G., & Beuschlein, F. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0654-5251 · Cited by 31
“[69] Due to the proximal myopathy as described above, postoperative muscle-training and physiotherapy should be recommended.”
BackgroundNachawi, N., Li, D., & Lansang, M. C. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23039 · Cited by 34
Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient’s Perspective
Claessen, K. M. J. A., Andela, C. D., Biermasz, N. R., & Pereira, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701365 · Cited by 33
Shriyan, P., Sudhir, P. M., van Schayck, O. C. P., & Babu, G. R. (2023) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2023.100196 · Cited by 36
“15,16 Studies during pregnancy investigating the effects of the HPA on birth outcomes and maternal mental health status have shown mixed results.”
Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency
Greve, J., Straßen, U., Gorczyza, M., Dominas, N., Frahm, U., Mühlberg, H., Wiednig, M., Zampeli, V., & Magerl, M. A. K. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12856 · Cited by 25
Karling, P., Norrback, K., Adolfsson, R., & Danielsson, Å. (2007) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520701395945 · Cited by 30
Güven, A., Karadeniz, S., Aydın, O., Akbalik, M., & Aydın, M. (2005) · Hormone Research in Paediatrics · doi:10.1159/000087288 · Cited by 24
“This complication is reversible in the majority of cases after a gradual withdrawal of steroids [”
Pemberton, S., & Cox, D. L. (2013) · Disability and Rehabilitation · doi:10.3109/09638288.2013.874503 · Cited by 31
Addiction and the adrenal cortex
Vinson, G. P., & Brennan, C. H. (2013) · Endocrine Connections · doi:10.1530/ec-13-0028 · Cited by 29
Transient psychosis in women on clomiphene, bromocriptine, domperidone and related endocrine drugs
Seeman, M. V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1060957 · Cited by 21
“period, the postpartum period and menopause [58].”
Jeronimo, G., Nozoe, K. T., Polesel, D. N., Moreira, G. A., Tufik, S., & Andersen, M. L. (2015) · Nutrition · doi:10.1016/j.nut.2015.09.004 · Cited by 23
Hypothalamic–pituitary–adrenal axis recovery after treatment of Cushing's syndrome
Balaško, A., Zibar, K., Kaštelan, D., & Dušek, T. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13172 · Cited by 21
“of fatigue, myalgia, decreased quality of life, arthralgia, depression, and anxiety, which are the result of a relative decrease in serum glucocorticoid concentrations and are called glucocorticoid withdrawal symptoms (GWS).(10) The pathophysiology of GWS is not completely Received: 16 March 2022 Revised: 30 May 2022…”
BackgroundPemberton, S., & Cox, D. L. (2013) · Journal of Occupational Science · doi:10.1080/14427591.2013.804619 · Cited by 26
Diagnosis and Differential Diagnosis of Cushing’s Syndrome
Findling, J. W., Nieman, L. K., & Tabarin, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705984 · Cited by 21
Cushing disease in pediatrics: an update
Concepción‐Zavaleta, M. J., Flórez, C. D. A., Aldave, J. E. Q., García-Villasante, E. J., Gariza-Solano, A. C., Durand‐Vásquez, M. D. C., Urteaga, L. A. C., & Zavaleta‐Gutiérrez, F. E. (2023) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2346074.037 · Cited by 20
Hormone replacement therapy in menopausal women: Past problems and future possibilities
Schmidt, J. W., Wollner, D. A., Curcio, J. J., Riedlinger, J. E., & Kim, L. S. (2006) · Gynecological Endocrinology · doi:10.1080/09513590600927017 · Cited by 21
“This ‘trapping’ effect, or dependency, of estrogen supplementation can be considered a side-effect of estrogen therapy and is an example of a general phenomenon observed when neuroactive substances are administered and then withdrawn [9].”
BackgroundRaschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac359 · Cited by 17
The unresolved riddle of glucocorticoid withdrawal
Pérez, F. G., Marengo, A. P., & Artero, C. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0691-1 · Cited by 18
Chacón, A. G. M., Wang, C., Waqar, D., Syeda, S. A., Kumar, R., & Meghana, D. R. (2023) · Cureus · doi:10.7759/cureus.38948 · Cited by 28
“During the discontinuation of GCs therapy, clinicians should anticipate glucocorticoid withdrawal syndrome, symptoms of adrenal insufficiency, and a possible relapse of the original disease prior to the treatment [74, 75].”
BackgroundMarkou, Α., Tsigou, K., Papadogias, D., Kossyvakis, K., Vamvakidis, K., Kounadi, T., & Piaditis, G. P. (2005) · HORMONES · doi:10.14310/horm.2002.11162 · Cited by 19
“A cortisol deprivation syndrome after cessation of suprophysiological glucocorticoid levels has been well described and favors this assumption.(28)”
MethodKonishi, K., Kumashiro, M., Izumi, H., & Higuchi, Y. (2008) · Industrial Health · doi:10.2486/indhealth.46.253 · Cited by 18
Predicting recovery of the hypothalamic-pituitary-adrenal axis after prolonged glucocorticoid use
Leong, S. H., Shander, S., & Ratnasingam, J. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0074 · Cited by 15
Close encounters with oxytocin
Carter, C. S. (2023) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2023.100189 · Cited by 14
“elicits withdrawal symptoms when they are stopped [81,82].”
BackgroundThe Glucocorticoid Taper: A Primer for the Clinicians
Priya, G., Laway, B. A., Ayyagari, M., Gupta, M., Bhat, G. H. K., & Dutta, D. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_410_23 · Cited by 14
El suicidio y algunos de sus correlatos neurobiológicos. Segunda parte
Gutiérrez‐García, A. G., & Contreras, C. M. (2008) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 19
Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
Maurer, M., Magerl, M. A. K., Aygören‐Pürsün, E., Bork, K., Farkas, H., Longhurst, H. J., Kiani‐Alikhan, S., Bouillet, L., Boccon‐Gibod, I., Cancian, M., et al. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-021-00644-0 · Cited by 12
(2018) · Romanian Journal of Anaesthesia and Intensive Care · doi:10.21454/rjaic.7518.252.rzn · Cited by 40
Torpy, D. J., & Lim, W. T. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52140 · Cited by 13
Metadata
- Authors
- Hochberg, Z., Pacak, K., & Chrousos, G. P.
- Affiliations
- National Institutes of Health (US)
- Pediatric and Reproductive Endocrinology Branch (Z.H., K.P., G.P.C.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2003-08-01
- Volume
- 24
- Issue
- 4
- Pages
- 523-538
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2033339602
- Cited by
- 181
- References
- 176
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 14 · 2023: 13 · 2022: 14 · 2021: 5 · 2020: 7 · 2019: 3 · 2018: 14 · 2017: 6 · 2016: 7 · 2015: 8 · 2014: 5 · 2013: 10 · 2012: 4
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- hormone dependence, hormone hypersecretion, hypothalamic-pituitary-adrenal axis, opioid peptides, noradrenergic system, dopaminergic system, hormone receptor signaling, transcription factors, hormone-producing tumors, antidepressants, stress prevention
- MeSH terms
- Androgens, Endocrine System, Estrogens, Female, Glucocorticoids, Hormones, Humans, Hypothalamo-Hypophyseal System, Male, Pituitary-Adrenal System, Substance Withdrawal Syndrome, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.